Cargando…

Medium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus

OBJECTIVE: The aim of this study was to analyze the changes in daily blood glucose fluctuation and insulin dose in patients with type 1 diabetes mellitus (T1DM) undergoing basal-bolus therapy following a switching of basal insulin used from insulin glargine or detemir to insulin degludec. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakae, Rie, Kusunoki, Yoshiki, Katsuno, Tomoyuki, Tokuda, Masaru, Akagami, Takafumi, Murai, Kazuki, Hamaguchi, Tomoya, Miyagawa, Jun-ichiro, Namba, Mitsuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070468/ https://www.ncbi.nlm.nih.gov/pubmed/24838615 http://dx.doi.org/10.1007/s40268-014-0048-6

Ejemplares similares

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine
por: Watanabe, Kahori, et al.
Publicado: (2016)

Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data
por: Murai, Kazuki, et al.
Publicado: (2014)

Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme‐linked immunosorbent assay
por: Matsuo, Toshihiro, et al.
Publicado: (2015)

Incretin responses to oral glucose load in Japanese non-obese healthy subjects
por: Nagai, Etsuko, et al.
Publicado: (2011)

Effects of the naturally‐occurring disaccharides, palatinose and sucrose, on incretin secretion in healthy non‐obese subjects
por: Maeda, Aya, et al.
Publicado: (2013)

Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2010)

Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
por: Konya, Hiroyuki, et al.
Publicado: (2013)

Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks
por: Hamaguchi, Tomoya, et al.
Publicado: (2011)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
por: Konya, Hiroyuki, et al.
Publicado: (2014)

Association of time in range with hemoglobin A1c, glycated albumin and 1,5‐anhydro‐d‐glucitol
por: Ohigashi, Mana, et al.
Publicado: (2020)

Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial
por: Iwamoto, Yasuhiko, et al.
Publicado: (2013)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
por: Demir, Tevfik, et al.
Publicado: (2021)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
por: Haahr, Hanne, et al.
Publicado: (2016)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
por: Thalange, Nandu, et al.
Publicado: (2015)

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus
por: Korsatko, S., et al.
Publicado: (2013)

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
por: Ikushima, Ippei, et al.
Publicado: (2015)

Effectiveness of Insulin Degludec in Thai Patients with Diabetes Mellitus: Real-World Evidence From a Specialized Diabetes Center
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2021)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
por: Haahr, Hanne, et al.
Publicado: (2014)

Insulin degludec aspart: One-year real world experience
por: Kalra, Sanjay, et al.
Publicado: (2016)

Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions
por: Kalra, Sanjay, et al.
Publicado: (2015)

Insulin degludec in the first trimester of pregnancy: Report of two cases
por: Milluzzo, Agostino, et al.
Publicado: (2017)

Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes
por: Henao-Carrillo, Diana Cristina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dg8bsgh87ung0v74m7fglq8h8v